Compare GTN & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | DNA |
|---|---|---|
| Founded | 1897 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.5M | 488.9M |
| IPO Year | 1996 | 2020 |
| Metric | GTN | DNA |
|---|---|---|
| Price | $4.79 | $6.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,095,000,000.00 | $170,155,000.00 |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.55 | $5.37 |
| 52 Week High | $6.44 | $17.58 |
| Indicator | GTN | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 42.02 |
| Support Level | $4.24 | $6.30 |
| Resistance Level | $5.05 | $7.10 |
| Average True Range (ATR) | 0.18 | 0.45 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 24.32 | 21.12 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.